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Abstract The death receptor 5 (DR5) is a receptor for tumor
necrosis factor-related apoptosis-inducing ligand and is able to
induce apoptosis in various tumor cells. The expression of DR5 is
up-regulated at the transcriptional level by p53, genotoxic stress
and so on. To investigate the structure of the DR5 gene
promoter, we screened and sequenced a genomic clone containing
the 5P-flanking region of the DR5 gene. RNase protection assays
showed two major transcription start sites around 3122 and
3137 upstream of the translation initiation codon ATG.
Transient transfections with serial 5P-deletion mutants identified
the minimal promoter element spanning 3198 to 3116. Site-
directed mutagenesis demonstrated that the DR5 gene promoter
has no typical TATA-box, but has two Sp1 sites responsible for
the basal transcription activity of the DR5 gene
promoter. ß 2001 Federation of European Biochemical Soci-
eties. Published by Elsevier Science B.V. All rights reserved.
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1. Introduction
Death receptor 5 (DR5, also called tumor necrosis factor
(TNF)-related apoptosis-inducing ligand (TRAIL)-R2, Apo2,
TRICK2 or KILLER) [1^5] is a member of the TNF receptor
family and is a receptor for TRAIL [1^5]. TRAIL is selec-
tively cytotoxic against tumor cells but not against normal
cells in vitro and in vivo [6^10], which therefore make it a
good target molecule for cancer therapy. To date, four recep-
tors for TRAIL including DR4, DR5, DcR1 and DcR2 have
been identi¢ed [1^5,11]. DR4 and DR5 induce apoptosis
through an intracellular death domain [1^5]. In contrast,
DcRs do not induce apoptosis due to the presence of muta-
tion or deletion in the death domain [1^5,11]. On the other
hand, a tumor-suppressor gene p53 has been reported to
transactivate DR5 gene expression [12^14]. In addition, geno-
toxic reagents such as doxorubicin, etoposide and MMS, and
Q-radiation are also known to induce the expression of DR5 in
a p53-dependent or -independent manner [15^19]. The syn-
thetic retinoid CD437 induces apoptosis together with up-reg-
ulation of DR5 in lung and prostate carcinoma cells [20^22].
Moreover, the synthetic glucocorticoid dexamethasone and
the cytokine interferon-Q induce apoptosis and DR5 expres-
sion in cell lines with mutant p53 [23].
As stated above, DR5 gene is a key target molecule for
cancer therapy and the expression of the gene is regulated
by a variety of factors. However, even the basic structure of
the DR5 promoter has not been reported. To investigate the
regulatory mechanisms of DR5 gene expression, it is crucial to
determine the basic structure of the DR5 gene promoter.
Thus, in this study, we clari¢ed the basic structure, transcrip-
tion initiation sites, and minimal promoter elements of the
human DR5 gene promoter.
2. Materials and methods
2.1. Cloning of the DR5 promoter region
On the basis of human DR5 cDNA sequences [1^5], two oligo-
nucleotides, 5P-CCGCAATCTCTGCGCCCACAAAATACACCG
(sense) and 5P-GTTTCAGCCCTTAAAGTAGATCGGGCATCG
(antisense), were synthesized. These oligonucleotides were labeled
with [Q-32P]ATP for use as probes, and used to screen the human
VPS library (Mo Bi Tec, Go«ttingen, Germany).
2.2. RNase protection assay
PCR products produced from DR5 genomic DNA were subcloned
into the pGEM T-easy vector (Promega). RNA probes were synthe-
sized with T7 RNA polymerase (MAXI script, Ambion). The RNase
protection assay was carried out using an RPA III kit (Ambion). The
sequencing reaction for preparing size markers was performed using a
T7 Sequencing kit (Amersham Pharmacia Biotech).
2.3. Plasmid construction
SacI^NcoI fragment digested from the DR5 promoter region of
genomic DNA was subcloned into the SacI^NcoI site of pGVB2 lu-
ciferase assay vector (Toyo ink, Tokyo, Japan) to produce pDR5/
SacI. pDR5/BamHI was generated by subcloning BamHI^NcoI frag-
ment of DR5 genomic DNA into pGVB2. Other deletion mutants
were generated with deletion kits (Takara, Tokyo, Japan) after
SacI^HindIII digestion of pDR5/SacI. Mutations in the TATA-like
box and two Sp1 sites were generated with a QuickChange Site-Di-
rected Mutagenesis kit (Stratagene).
2.4. Cell culture, transfection and luciferase assays
MCF7 cells were maintained at 37‡C in Dulbecco’s modi¢ed Eagle
medium with 10% fetal calf serum. Culture cells (3U104/well) were
seeded on 12-well plates 24 h before transfection. Plasmids (0.5 Wg)
were transfected into cells using the DEAE-dextran method (Cell-
Phect, Amersham Pharmacia Biotech). After 48 h, the cells were har-
vested. Then luciferase assays were performed using luciferase assay
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reagents (Promega) and a luminometer. Each experiment was repeated
at least three times. Transfection e⁄ciency was standardized by co-
transfection of the pACT-L-galactosidase (L-gal) plasmid (kind gift
from Dr. S. Ishii). Data were analyzed using a Student’s t-test and
di¡erences were considered signi¢cant from controls when P6 0.05.
3. Results and discussion
3.1. Cloning and nucleotide sequence of the 5P-£anking region
of human DR5 gene
We carried out molecular cloning, and clari¢ed the sequen-
ces of the 5P-£anking region of DR5 gene from a human
genomic library. As shown in Fig. 1, there are multiple po-
tential transcription regulatory factor binding sites that might
transcriptionally regulate DR5 gene expression, such as c-Ets
2, AML-1a, c-Myb, Sp1 and GATA-1. The p53 transactivates
DR5 gene through an intronic p53 binding site [14]. We also
found a p53 binding site at the same region (+235 to +254).
Interestingly, the nuclear factor UB (NFUB) binding site lies
between +385 and +394 in intron 1. Gibson et al. reported
that the increase in DR5 expression following etoposide treat-
ment was blocked by inhibition of NFUB activation, and pro-
posed that etoposide-induced expression of DR5 is mediated
through an NFUB signaling pathway [15]. In addition, NFUB
stimulates TRAIL-induced apoptosis by activation of DR5
[24]. It might be possible that the NFUB activates DR5 ex-
Fig. 1. The 5P-£anking region of the human DR5 gene. The ATG translational initiation codon is shown by the double underline and the ad-
enine residue is designated as +1. The binding sites of potential transcription factors are underlined and indicated below the sequence. The
transcription start sites mapped in Fig. 2 are demonstrated with arrowheads. The terminal ends of 5P-deleted constructs are shown at each
base. The coding region in exon 1 is boxed.
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pression via the binding site in intron 1. The sequence between
3680 and 3541 of the 5P-£anking region of the DR5 gene was
rich in G and A. TRAIL is a ligand for DR5, and the pro-
moter region of TRAIL also contains a GA rich region [25].
Both DR5 and TRAIL genes may be regulated via this region.
3.2. Identi¢cation of transcription initiation sites of DR5 gene
We performed an RNase protection assay to determine the
transcription initiation sites of the human DR5. Total RNAs
were prepared from MCF7 cells in which DR5 is expressed
[18]. RNAs were hybridized with DR5 genomic sequence-de-
rived RNA probes, and the RNA fragments digested by
RNase A and T1 were analyzed. The major longer signals
were detected around 3137 and 3122 upstream of the ¢rst
ATG translation start codon (Fig. 2, lane 1). These protection
patterns seemed to be sequence-speci¢c because yeast RNAs
did not provide such signals (Fig. 2, lane 2).
3.3. Demonstration of promoter activity of the DR5 gene
SacI^NcoI fragment of the 5P-£anking region of the DR5
gene was subcloned into luciferase assay vector and transient
luciferase assay was performed (Fig. 3). The full length con-
struct (pDR5/SacI) demonstrated enough luciferase activity
compared with that using vacant vector, pGVB2. This ¢nd-
ing indicates that the fragment of the 5P-£anking region has
authentic promoter activity. Next we generated a series of
5P-deletion mutants. In shorter constructs than pDR5/3605,
promoter activities gradually decreased. However, promoter
activities of DR5/3115 and DR5/338 were almost the same
as that of vacant vector, pGVB2. These ¢ndings indicate that
the region spanning 3198 to 3116 contains the minimal pro-
moter element of the human DR5 gene. Transcription start
sites (3137 and 3122) illustrated in Fig. 2 are contained with-
in this putative minimal promoter region, which supports this
idea.
3.4. Two Sp1 sites are involved in transcription activation of
the DR5 gene
The region spanning 3198 to 3116 contains two Sp1 sites
and a TATA-like box site as typical transcription factor bind-
ing sites (Fig. 1). Next, we generated constructs harboring
mutations in the TATA-like box and two Sp1 sites, and car-
Fig. 2. RNase protection assay to determine the transcription start
sites of the human DR5 gene. 32P-labeled antisense riboprobe span-
ning 3347 to +45 was hybridized to total RNA isolated from
MCF7 cells and yeast tRNA. The fragments protected by RNase A
and T1 digestion were separated on a denaturing polyacrylamide
gel. Major transcription start sites at 3137 and 3122 (arrows) were
identi¢ed by comparison to the nucleotide sequence of M13 mp18
ssDNA. *: non-digested riboprobe.
Fig. 3. Deletion analysis of DR5 gene promoter. The reporter plasmids containing various sizes of 5P-deleted human DR5 promoter and lucifer-
ase genes were transfected into MCF7 cells. Each activity was normalized by the activity of cotransfected pACT-L-gal (kind gift from Dr. S.
Ishii). Data are shown as means þ S.E. (n = 3). Structures of relevant plasmids used in this experiment are shown on the left. *P6 0.01.
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ried out the transient luciferase assay (Fig. 4). Each mutation
in the Sp1 sites decreased the promoter activity. In contrast,
mutations in the TATA-like box somewhat stimulated the
promoter activity. These ¢ndings indicate that the DR5 gene
promoter is a TATA-less promoter, and that the two Sp1 sites
are important for basal transcription activity. Ubiquitously
expressed genes often lack a TATA-box but have GC-boxes
such as Sp1 binding sites within their promoters [26,27]. The
human DR5 gene is expressed ubiquitously in multiple tissues.
The ¢ndings of this study show that the human DR5 gene
promoter belongs to the class of ubiquitously active, TATA-
less and GC-box-containing promoters.
The DR5 gene is regulated by p53, which is a tumor-sup-
pressor gene and de¢cient in more than half of all malignant
tumors. Therefore, chemical compounds that can stimulate
the DR5 gene should compensate for the absent function of
p53. We proposed that methods of up-regulating p53 target
genes would be useful for cancer therapy, and termed this
method ‘gene-regulating chemotherapy’ [28,29]. As a model
for this, histone deacetylase inhibitors such as butyrate or
trichostatin A stimulate the p21/WAF1 gene, being a p53
target gene, through the Sp1 sites of the promoter indepen-
dent of p53, resulting in cell cycle arrest [30,31]. Thus, our
¢ndings and methods in this report may be useful for screen-
ing the regulators of human DR5 gene expression, and for
analyzing these regulatory mechanisms in the hope that this
will lead to novel cancer therapy.
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